Semaglutide and Tirzepatide Trial to Assess Genetic Aging Delay in Obese Adults
Semaglutide and Tirzepatide for Genetic Aging Delay in Adults With Obesity
Study Design
Intervention
Semaglutide or Tirzepatide, dose and route not specified, for 24 weeks.
Comparator
Metformin.
Outcome
Impact on genetic aging.
Abstract
A randomized trial will compare semaglutide, tirzepatide, and metformin in 66 obese adults to assess their impact on genetic aging over 24 weeks.